The phase III KEYNOTE-177 trial evaluating first-line treatment of Keytruda in patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer met one of its dual primary endpoints of progression-free survival.
The primary endpoint was met in a predefined step-1 analysis of a phase III trial in non-small cell lung cancer patients treated with Tedopi, a neoepitope cancer vaccine.
Caris Life Sciences launched MI FOLFOXai, an artificial intelligence-based predictor of response to FOLFOX chemotherapy in metastatic colorectal cancer that demonstrated approximately 50% improvement in overall survival across two independent validation studies.
As oncologists, we are all too familiar with making treatment recommendations and advising on end-of-life care in the absence of robust data. In ethical conundrums, we rely on guidance from our colleagues in the field, institutions, and national/international leadership bodies.
The American Association for Cancer Research board of directors sent the following letter to congressional leadership March 30.
In a public letter to the American Hospital Association, 54 health care organizations condemned attempts by hospital administrators to muzzle health care workers who speak out against coronavirus caseloads and supply shortages.
The following is a statement from the American College of Surgeons.
Cancer Prevention and Research Institute of Texas has suspended its first cycle of grant applications for fiscal year 2021 for Academic Research, Product Development Research and Prevention Program awards.
In a report published by the American Enterprise Institute, former FDA Commissioner Scott Gottlieb proposes a road map for navigating COVID-19 in the United States.
The Centers for Medicare & Medicaid Services March 30 issued regulatory waivers and new rules to respond to the 2019 novel coronavirus pandemic.
